Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2021
FDA approves Lybalvi
The US Food and Drug Administration approved Alkermes’ Lybalvi for the treatment of schizophrenia and bipolar I disorder.
2021
Alkermes and MSD enter clinical trial collaboration
Alkermes announced a clinical trial collaboration and supply agreement with MSD for a planned phase 3 study evaluating nemvaleukin alfa in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer. Alkermes is responsible for conducting the study, which was planned to initiate in the second half of 2021.
2021
Alkermes appoints COO and names CFO
Alkermes appointed Blair Jackson as chief operating officer and named Iain Brown chief financial officer, replacing James Frates.
2020
Alkermes withdraws 2020 financial expectations
Alkermes withdrew its previously provided 2020 financial expectations, citing uncertainty about the impact of the COVID-19 pandemic on its operating and financial results.
2020
Alkermes reports first-quarter 2020 results
Alkermes reported first-quarter 2020 financial results, including revenue of $246.2 million and a GAAP net loss of $38.7 million.
2020
Stafford family files wrongful-death suit against Alkermes over Vivitrol
The parents of a man who died of an opioid overdose sued Alkermes. The wrongful-death suit alleges that Alkermes failed to warn of overdose risks after patients stop taking Vivitrol and relapse, and claims the medication is ineffective and deceptively marketed. Alkermes said it stands by Vivitrol’s efficacy and safety and will vigorously defend the matter.
2020
Alkermes sued over Vivitrol-related overdose death
The parents of a man who died of an opioid overdose sued Alkermes. The wrongful-death suit alleges that Alkermes failed to warn of overdose risk after patients stop taking Vivitrol and relapse, and also alleges that Vivitrol is ineffective and deceptively marketed. Alkermes said it stands by the drug's efficacy and safety and will vigorously defend the matter.
2019
Alkermes completes acquisition of Rodin Therapeutics
Alkermes announced that it had completed its previously announced acquisition of Rodin Therapeutics. The transaction expands Alkermes’ CNS development efforts into neurodegenerative disorders.